Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons

Adel Naimi; Rebar N. Mohammed; Ahmed Raji; Supat Chupradit; Alexei Valerievich Yumashev; Wanich Suksatan; Mohammed Nader Shalaby; Lakshmi Thangavelu; Siavash Kamrava; Navid Shomali

doi:10.1186/s12964-022-00854-y

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons

Identifier:nobleid.org/w1/20260526/FD642F72

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/FD642F72.svg?ark=w1%2F20260526%2FFD642F72)](https://nobleid.org/work/w1/20260526/FD642F72)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Alexei Valerievich Yumashev

Wanich Suksatan

Mohammed Nader Shalaby

Lakshmi Thangavelu

Siavash Kamrava

Navid Shomali

Claim authorship of this work

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons

Identifier:nobleid.org/w1/20260526/FD642F72

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/FD642F72.svg?ark=w1%2F20260526%2FFD642F72)](https://nobleid.org/work/w1/20260526/FD642F72)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Alexei Valerievich Yumashev

Wanich Suksatan

Mohammed Nader Shalaby

Lakshmi Thangavelu

Siavash Kamrava

Navid Shomali

Claim authorship of this work